Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Primary Hyperoxaluria

Kidney & Renal

Primary Hyperoxaluria (PH1) Clinical Trials and Treatments

Also called PH1, primary hyperoxaluria type 1, oxalosis, glycolic aciduria, primary oxaluria

Primary hyperoxaluria type 1 is an autosomal recessive disorder caused by deficiency of the liver enzyme alanine-glyoxylate aminotransferase (AGT), encoded by the AGXT gene. Without functional AGT, glyoxylate is not properly converted to glycine and instead is oxidized to oxalate. The liver continuously overproduces oxalate, which is excreted by the kidneys. As urinary oxalate exceeds the saturation threshold, calcium oxalate crystals form, causing recurrent nephrolithiasis (kidney stones) and progressive nephrocalcinosis.

In plain words, primary hyperoxaluria is a rare inherited condition where the liver makes too much of a waste substance called oxalate. Oxalate mixes with calcium to form kidney stones, which can slowly damage the kidneys over time.

Get an email when new Primary Hyperoxaluria trials open or the FDA decides. Get alerts

Primary Hyperoxaluria

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 4 studies with no phase, like observational studies, and 1 combined-phase study, such as Phase 1/2, counted at the later phase.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines2

Rivfloza · Oxlumo

Primary Hyperoxaluria has 2 FDA-approved medicines, 10 open or active clinical trials (10 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Primary Hyperoxaluria

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Primary Hyperoxaluria

As kidney function declines, the kidneys become unable to clear the excess oxalate, leading to systemic oxalosis where calcium oxalate deposits accumulate in bones, blood vessels, skin, retina, heart, and other organs. Without treatment, PH1 typically progresses to end-stage kidney disease, often requiring combined liver-kidney transplantation.

Keep reading about Primary Hyperoxaluria

Alnylam's OXLUMO (lumasiran), an RNAi therapy that silences the HAO1 gene to reduce oxalate production, was FDA-approved in 2020 and has dramatically changed the treatment paradigm. Lumasiran reduces urinary oxalate by approximately 65% and can potentially prevent kidney failure when started early. Conservative measures including high fluid intake and citrate supplementation remain important adjuncts.

What are the symptoms of Primary Hyperoxaluria?

These are common symptoms of Primary Hyperoxaluria, and how strong they are varies from person to person.

  • Recurrent kidney stones, often starting in childhood
  • Blood in the urine
  • Severe abdominal or flank pain from kidney stones
  • Recurrent urinary tract infections
  • Progressive kidney disease that may lead to kidney failure
  • In advanced cases, oxalate deposits in bones, eyes, heart, and skin (systemic oxalosis)

Who gets Primary Hyperoxaluria?

Can present from infancy through adulthood, though most cases of PH1 are diagnosed in childhood or adolescence. Affects males and females equally. Autosomal recessive inheritance. More common in certain populations in the Middle East and North Africa. Estimated that up to 50% of cases remain undiagnosed.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Primary Hyperoxaluria?

There are currently 2 FDA-approved medications for Primary Hyperoxaluria.

nedosiran
Novo Nordisk (developed by Dicerna Pharmaceuticals)
Search
lumasiran

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Primary Hyperoxaluria treatment

Charity funds and drugmaker programs for Primary Hyperoxaluria, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
Status as each foundation showed it on November 16, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Primary Hyperoxaluria, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Primary Hyperoxaluria

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Primary Hyperoxaluria resources

Reputable organizations and medical references for learning more about Primary Hyperoxaluria, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Primary Hyperoxaluria

Use this Primary Hyperoxaluria clinical trial finder to see the 10 studies recruiting patients in the United States and worldwide, with eligibility criteria in plain English. Of these, 6 test a treatment and 4 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

10 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 3Recently updatedNCT06465472

Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3

Intervention: Stiripentol Oral Capsule, Placebo Oral Capsule, Urine samples collect, Blood samples collect, Kidney imaging, Quality of Life questionnaires

Sponsor: Biocodex

Evaluation of the efficacy and safety of stiripentol in patients 6 years and older with primary hyperoxaluria type 1, 2 or 3.

Ages 6 Years+1 location
Started Sep 2026Updated 1 week agoEst. Aug 2030 (~3y 9m)
RecruitingTreatment trialPhase 1/2Recently updatedNCT06839235

Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)

Intervention: ABO-101

Sponsor: Arbor Biotechnologies

The goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperoxaluria type 1 (PH1). The trial will consist of 2 Study Periods. During the first Study Period, there will be 2 parts.

Ages 6 Years to 64 Years
Started Jun 2025Updated 1 month agoEst. Mar 2029 (~2y 4m)
RecruitingTreatment trialPhase 2Recently updatedNCT07587021

Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)

Intervention: YOLT-203, Placebo

Sponsor: YolTech Therapeutics Co., Ltd

This study will be conducted to evaluate the efficacy and safety of YOLT-203 in children and adults with Primary Hyperoxaluria Type 1.

Ages 6 Years+4 locations
Started Sep 2026Updated 1 month agoEst. Aug 2027 (~9 months)
RecruitingTreatment trialPhase 1Updated a few months agoStart date still listed as an estimateNCT07776626

Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1)

Intervention: YOLT-203

Sponsor: YolTech Therapeutics Co., Ltd

This is a single-arm, open-label, single-dose dose-escalation study. It aims to evaluate the safety and tolerability of YOLT-203 in Chinese patients with Primary Hyperoxaluria Type 1 (PH1), and to preliminarily assess the effect of a single administration of YOLT-203 on 24-hour urinary oxalate excretion.

Ages 6 Years+1 location
Expected to start Aug 2026Updated 3 months agoEst. Oct 2027 (~11 months)
RecruitingObservational study, no treatment givenUpdated a few months agoNCT02026388

Rare Kidney Stone Consortium Biobank

Sponsor: Mayo Clinic

This study is being done to obtain samples from patients with primary hyperoxaluria, cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent disease, and from their family members, for use in future research.

Ages not specified1 location
Started May 2013Updated 4 months agoEst. Jun 2030 (~3y 7m)
Find Primary Hyperoxaluria trials near you, ranked by distance →
Active trial locations9 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+1 more

Trial Pipeline

Jan 2021 to Nov 2031; studies that began earlier start at the left edge
2021
2023
2025
2027
2029
2031
now
Early Phase 1
Phase 1
Phase 2
Phase 3
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Primary Hyperoxaluria trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Primary Hyperoxaluria foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Primary Hyperoxaluria patient communities

Facebook groups, Reddit communities and YouTube channels where Primary Hyperoxaluria patients, caregivers and advocacy groups talk.

Companies developing Primary Hyperoxaluria treatments

Drugmakers that list Primary Hyperoxaluria in their rare disease portfolio, 2 in all.

Questions people ask about Primary Hyperoxaluria